Literature DB >> 24967767

A patient with acute liver failure and extreme hypoglycaemia with lactic acidosis who was not in a coma: causes and consequences of lactate-protected hypoglycaemia.

G Oldenbeuving1, J R McDonald, M L Goodwin, R Sayilir, D J Reijngoud, L B Gladden, M W N Nijsten.   

Abstract

Lactate can substitute for glucose as a metabolic substrate. We report a patient with acute liver failure who was awake despite a glucose level of 0.7 mmol/l with very high lactate level of 25 mmol/l. The hypoglycaemia+hyperlactataemia combination may be considered paradoxical since glucose is the main precursor of lactate and lactate is reconverted into glucose by the Cori cycle. Literature relevant to the underlying mechanism of combined deep hypoglycaemia and severe hyperlactataemia was assessed. We also assessed the literature for evidence of protection against deep hypoglycaemia by hyperlactataemia. Four syndromes demonstrating hypoglycaemia+hyperlactataemia were found: 1) paracetamol-induced acute liver failure, 2) severe malaria, 3) lymphoma and 4) glucose-6-phosphatase deficiency. An impaired Cori cycle is a key component in all of these metabolic states. Apparently the liver, after exhausting its glycogen stores, loses the gluconeogenic pathway to generate glucose and thereby its ability to remove lactate as well. Several patients with lactic acidosis and glucose levels below 1.7 mmol/l who were not in a coma have been reported. These observations and other data coherently indicate that lactate-protected hypoglycaemia is, at least transiently, a viable state under experimental and clinical conditions. Severe hypoglycaemia+hyperlactataemia reflects failure of the gluconeogenic pathway of lactate metabolism. The existence of lactate-protected hypoglycaemia implies that patients who present with this metabolic state should not automatically be considered to have sustained irreversible brain damage. Moreover, therapies that aim to achieve hypoglycaemia might be feasible with concomitant hyperlactataemia.

Entities:  

Keywords:  coma; gluconeogenesis; hyperlactataemia; hypoglycaemia; paracetamol

Mesh:

Substances:

Year:  2014        PMID: 24967767     DOI: 10.1177/0310057X1404200413

Source DB:  PubMed          Journal:  Anaesth Intensive Care        ISSN: 0310-057X            Impact factor:   1.669


  7 in total

Review 1.  Lactate metabolism: historical context, prior misinterpretations, and current understanding.

Authors:  Brian S Ferguson; Matthew J Rogatzki; Matthew L Goodwin; Daniel A Kane; Zachary Rightmire; L Bruce Gladden
Journal:  Eur J Appl Physiol       Date:  2018-01-10       Impact factor: 3.078

Review 2.  Lactate and cancer: revisiting the warburg effect in an era of lactate shuttling.

Authors:  Matthew L Goodwin; L Bruce Gladden; Maarten W N Nijsten; Kevin B Jones
Journal:  Front Nutr       Date:  2015-01-05

3.  The association of early combined lactate and glucose levels with subsequent renal and liver dysfunction and hospital mortality in critically ill patients.

Authors:  Pedro Freire Jorge; Nienke Wieringa; Eva de Felice; Iwan C C van der Horst; Annemieke Oude Lansink; Maarten W Nijsten
Journal:  Crit Care       Date:  2017-08-21       Impact factor: 9.097

4.  Ischemic priapism as a model of exhausted metabolism.

Authors:  Sanne Vreugdenhil; Pedro J Freire Jorge; Mels F van Driel; Maarten W Nijsten
Journal:  Physiol Rep       Date:  2019-03

5.  Evaluation of bioenergetic and mitochondrial function in liver transplantation.

Authors:  Rui Miguel Martins; João Soeiro Teodoro; Emanuel Furtado; Anabela Pinto Rolo; Carlos Marques Palmeira; José Guilherme Tralhão
Journal:  Clin Mol Hepatol       Date:  2019-03-22

Review 6.  Hepatocrinology.

Authors:  Sanjay Kalra; Saptarshi Bhattacharya; Pawan Rawal
Journal:  Med Sci (Basel)       Date:  2021-06-01

7.  Repeated Activation of Noradrenergic Receptors in the Ventromedial Hypothalamus Suppresses the Response to Hypoglycemia.

Authors:  Anne-Sophie Sejling; Peili Wang; Wanling Zhu; Rawad Farhat; Nicholas Knight; Daniel Appadurai; Owen Chan
Journal:  Endocrinology       Date:  2021-03-01       Impact factor: 5.051

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.